New global guideline published on managing fungal infections caused by Candida
A new global guideline for the diagnosis and treatment of Candidainfections was recently published in Lancet Infectious Diseases1. This guideline sets out new standards for managing fungal infections, which affect millions of people worldwide every year.
The global guideline was developed by a team of more than 100 experts spanning 35 countries and led by Professor Dr. Oliver A. Cornely and Dr. Rosanne Sprute from University Hospital Cologne.
One year following the European Medical Association (EMA)2 approval, rezafungin ▼3 has been included in the guideline, along with other echinocandins, as a strongly recommended first line therapy option for the treatment of candidaemia.
Echinocandins, including rezafungin, are preferred for all forms of invasive candidiasis, excluding CNS and ocular infections, due to their broad antifungal activity and favourable safety profile.
The new guideline, which took four years to develop, contains recommendations for clinicians on the prevention, diagnosis and treatment of various forms of candidiasis, including innovative diagnostic procedures and the latest therapeutic approaches to help improve patient care.
The guideline is supported by more than 70 international expert associations including ECMM (European Confederation of Medical Mycology), ISHAM (International Society for Human and Animal Mycology) and ASM (American Society for Microbiology), who endorse its recommendations as an important guide for healthcare professionals.
About Mundipharma
Mundipharma is a global healthcare company focussing on customers across Africa, Asia Pacific, Canada, Europe, Latin America, and the Middle East.
Mundipharma is dedicated to bringing innovative treatments to patients in the areas of pain management, infectious disease as well as other severe and debilitating disease areas. Their guiding principles, centred around Integrity and Patient-Centricity, are at the heart of everything they do. For more information visit www.mundipharma.com.
References:
1. Cornely OA, et al. Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM. The Lancet Infectious Diseases 2025 available at: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00749-7/fulltext (last accessed February 2025).
2. European Medicines Agency approval. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/rezzayo#ema-inpage-item-assessment-history (last accessed February 2025).
3. REZZAYO® Product Information. EPAR Medicine Overview available at: https://www.ema.europa.eu/en/medicines/human/EPAR/rezzayo (last accessed February 2025).
Job code: GBL-RZF-2500015
Date of preparation: February 2025
View source version on businesswire.com: https://www.businesswire.com/news/home/20250220214452/en/
Contacts
Media contact:
Liana Del Medico
VP Communications & Corporate Affairs, Mundipharma
media.relations@mundipharma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alpha Blue Ocean Group Announces the Launch of its Investment Banking Service Provider Division: ABO Transaction Advisory Services. Pierre Vannineuse Steps Down as CIO of ABO’s Investment Division to Lead ABO Transaction Advisory Services Full Time21.2.2025 16:00:00 EET | Press release
ABO Group, a market leader in Europe for PIPE deals and complex public cross border M&As, announces the establishment of Alpha Blue Ocean Transaction Advisory Services LTD ("ABO-TAS"), a new division dedicated to offering Public Listing Advisory, Capital Raise Advisory, Non-Deal Roadshows, M&A, Management Consulting, Restructuring Advisory and other transaction advisory services. ABO TAS is fully segregated and separate from the Alpha Blue Ocean Group’s Investment Division (which carries out the traditional investment activities of the ABO Group). ABO Group’s investment banking services will leverage the decades of combined experience of the ABO TAS team in investment banking, Public ECM and DCM and most notably structured PIPEs and complex cross border transactions. On the consulting side, the ABO TAS team is dedicated to help businesses reach their maximum potential by capturing synergies between companies and its broad network of established relationships. To spearhead this initiati
Erectile Dysfunction: The PelviTouch Revolution Comes From DEKA’s Italian Technology21.2.2025 15:30:00 EET | Press release
DEKA Laser, a subsidiary of El.En. S.p.A., a company operating in the Laser and Energy-Based Devices market, listed on Borsa Italiana’s Euronext STAR Milan (“STAR”), and a global leader in medical technologies, has presented its latest innovative therapy, PelviTouch, for the treatment of erectile dysfunction, at the European Society for Sexual Medicine (ESSM) congress. This technology was initially developed, with great success, for the treatment of urinary incontinence for both sexes, and it has now been optimized and specialized by DEKA’s research and development team to improve men’s intimate health, with effective treatments aimed specifically at erectile dysfunction, a field in which the Italian company is an absolute pioneer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250221055364/en/ PelviTouch Therapy Presentation at ESSM Congress (Photo by DEKA) Paolo Salvadeo, DEKA’s CEO and El.En. S.p.A.’s General Manager, has
REPLY: Go Reply and Sprint Reply Automate the Creation of Clinical Study Reports for Dr. Willmar Schwabe with AI21.2.2025 12:01:00 EET | Press release
Go Reply, a leading Google Cloud Premier Partner, together with Sprint Reply, the Reply Group’s expert in strategic consulting and digital transformation, has developed an AI-driven tool for the pharmaceutical company Dr. Willmar Schwabe that streamlines the preparation of clinical study reports and ensures compliance with the highest scientific standards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250221805824/en/ By combining Go Reply's expertise in Google technologies with Sprint Reply’s ability to transform business models, a cutting-edge solution has been created that allows Dr. Willmar Schwabe's team to focus on what really matters: advancing research for innovative medicines to improve public health. (Graphic: Business Wire) To obtain marketing authorisation for its high-quality herbal drugs, Dr. Willmar Schwabe must rigorously test their efficacy, safety and tolerability in clinical trials. By leveraging the powe
KKR Invests in Stockholm Multifamily Housing Development Led by Reliwe and Derome21.2.2025 09:10:00 EET | Press release
Global investment firm KKR today announced the agreement with leading Swedish developers Reliwe and The Derome Group for the forward-purchase of three multifamily properties currently under development in Haninge, located just south of the Stockholm city center. The investment is being made by KKR's European Real Estate strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250220298047/en/ Credit: Reliwe / Lindberg Stenberg Arkitekter AB The development is comprised of three new properties totaling 382 residential units, expected to be completed between late 2026 and early 2027. Leading Swedish property developer Reliwe is overseeing the development, which includes two timber construction properties being built by Derome, a leading industrial business, and a third traditional concrete construction asset built to a high specification. The development is located adjacent to a bus terminal and railway station, offering excel
Digital Prosperity Awards Winners Announced at 4 th General Assembly of the Digital Cooperation Organization21.2.2025 00:09:00 EET | Press release
The Digital Cooperation Organization (DCO), the world's first standalone international intergovernmental organization focusing on the acceleration of the growth of an inclusive and sustainable digital economy, has unveiled the winners of the Digital Prosperity Awards at a ceremony held at its 4th General Assembly gala dinner hosted by the Hashemite Kingdom of Jordan, in the Dead Sea. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250220587577/en/ Digital Prosperity Awards winners announced at 4th General Assembly of the Digital Cooperation Organization (Photo: AETOSWire) Attended by high-level delegations from DCO’s 16 Member States, as well as DCO’s Observers, Partners, and distinguished guests, the Awards aim to acknowledge exceptional initiatives in adopting best practices, policies, and strategies to accelerate digital transformation in their respective countries. The objective is to accelerate digital economic advanceme
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom